Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal-dominantly-inherited vascular dysplasia characterized by age-dependant incomplete penetrance and variable expressivity, with clinical manifestations consisting in epistaxis, mucocutaneous telangiectases, gastrointestinal bleeding and arteriovenous malformations (AVMs), which affects approximately Yz million people world-wide. It affects males and females of all racial and ethnic groups. Up to Ih of HHT patients have multiple organ involvement, which can be disabling and/or life threatening. HHT can be treated successfully if correctly diagnosed. Morbidity of HHT is often due to complications of AVMs, such as stroke or haemorrhage, also known to occur in children. Many authors have reported successful new therapeutical options for AVMs, which have resulted in a significant decrease of life-threatening complications and HHT morbidity. Since early diagnosis permits an appropriate care of affected subjects, a very sensitive mutation screening technique is required to identify the mutation carriers among all at-risk individuals belonging to HHT-families. There may be one or more genes that cause HHT but, if so, they are quite rare. Currently, scientists are trying to better understand exactly how the abnormal gene can interfere with normal blood vessel formation and promote the phenotype of HHT, so that better treatments for the symptoms of HHT can be developed.
the various spectrum of its clinical manifestations.
HHT is characterized by age-dependant phenotypic penetrance, nearly complete by the age of 40. The expression of HHT is extremely variable with a great disparity of clinical manifestations between affected individuals and even among members of the same family. Genetic and epigenetic factors have been postulated to account for this diversity.
HHT clinical signs
The clinical manifestations are caused by direct arteriovenous connections without an intervening capillary bed. This can result in a range of malformations from smaller mucocutaneous telangiectases to large visceral arteriovenous malformations (AVM).
Clinical manifestations of HHT include recurrent epistaxis, multiple mucocutaneous telangiectases at characteristic sites (lips, oral cavity, facial skin, hands including fingers, auricles, thorax and nose) (2) , visceral lesions, such as gastrointestinal hemorrhages, pulmonary arteriovenous malformations (PAVMs), cerebral arteriovenous malformations (CAVMs) and hepatic arteriovenous malformations (HAVMs) (3) . Recurrent epistaxis is usually the first symptom and is present in more than 90% of patients with HHT (3) . The cutaneous and mucosal telangiectases occur more often in typical sites (fingertips, lips, oral cavity, conjunctivae, nasal mucosa) and begin generally by the age of 30 and 50 years. They are small raised lesions, bright red or purple-red in colour, which are very fragile and thus bleed easily, but this bleeding is rarely clinically important ( Fig. 1 ).
The dimension of telangiectases varies in time due to their slow but progressive enlargement and generally they also tend to increase in number ( Fig.  2 ). Telangiectases can be detected in more than 80% of HHT patients (3), but sometimes they are not visible or are barely visible with the naked eye. For this reason, capillary microscopy is a valuable tool in the diagnosis of HHT (4) . The alterations that can be observed are giant loops, often with tortuous configuration and prominent enlargement of the draining limb between normal capillaries.
Telangiectases are the hallmark of the disease, but may be difficult to distinguish from other diseases, like angiokeratoma corporis difJusum (Fabry syndrome), systemic sclerosis and ataxiatelangiectasia. Other problems to be considered are pregnancy, spider angioma in chronic alcoholism, calcinosis, Raynaud phenomenon, esophageal motility disorder, sclerodactily and teleangectasia (CREST syndrome). Treatment is rarely needed for skin lesions, but cosmetically disturbing or frequently bleeding lesions can be treated with laser therapy.
Arteriovenous malformations affect lung, brain, liver and, more rarely, spinal cord. (2) . Patients develop life-threatening complications such as severe gastrointestinal bleeding and arteriovenous malformations (AVMs) (direct connection between a dilated venule and arteriole, bypassing the capillary network) of the liver, lung or brain. The shunting of blood through pulmonary or cerebral AVMs can lead to hypoxemia, stroke, brain abscess, heart failure and fatal hemorrhage (3) . Gastrointestinal (GI) bleeding from intestinal telangiectatic lesions usually does not start before the fifth decade and may cause severe anemia (5) . GI bleeding is possible, generally in the form of chronic stillicidium, due to telangiectases in the esophageal gastric and intestinal mucosa (6) . The most common site of AVM is the lung. Pulmonary arteriovenous malformations are estimated to develop in more then 20% of the patients (3) . The presence of pulmonary arteriovenous fistulae (PAVMs) (3) is a relatively frequent event in HHTI. PAVMs result in a right to left shunt and thus hypoxemia, and may cause serious complications such as bleeding (hemothorax), bypass of emboli or bacteria causing serious systemic complications (7) such as stroke and cerebral abscess (3). Because of these serious complications, treatment of PAVMs is indicated, even when asymptomatic. Cerebral arteriovenous malformations (CAVMs) are less common, but are probably under-recognized, and are present in 10-15% of the patients (8) . Although they are often silent, they can cause headache, seizure, ischemia, bleeding, epilepsy and hemorrhagic stroke (break of aneurysms), sometimes with disabling consequences. (5, (9) (10) (11) (12) .
Hepatic arteriovenous fistulae (HAVMs) are very often asymptomatic and as a result, their treatment is not generally necessary and is applied only when they cause complications (13) . Organ transplantation is the treatment of choice for hepatic arteriovenous malformations in the presence of meaningful symptomatology (14) .
Clinical diagnostic criteria for HHT
Currently the diagnosis relies on strict association between molecular screening and clinical investigation, considering signs and symptoms, that allow the prompt identification and timely treatment of severe vascular alterations observed in gene mutation carriers in a pre-symptomatic stage.
According to the Curacao criteria (2), the diagnosis ofHHT is considered definite in an individual ifthree or more of the following four criteria are present and suspected if two of the following four criteria are present: 1) epistaxis -spontaneous and recurrent; 2) telangiectases -multiple, at characteristic sites, including lips, oral cavity, fingers and nose; 3) internal telangiectases or AVM-lung, brain, GI, liver or spinal; 4) family history -parent, sibling or child with HHT according to these criteria (2) .
Mutidisciplinary approach is the gold standard in HHT investigation. The most commonly used instrumental tests to investigate HHT patients are: an echocolor-Doppler of the portal system/area used to detect the survey of hepatic fistulae; arterial blood gas analysis and echocardiography with C.m. used to inquire into pulmonary shunts; thorax-abdomen multislice-Computed Tomography (CT) used as a check test; brain MRI performed in order to locate cerebral arteriovenous fistulae whereas esophagoga stroduodenoscopy (EGDS) is performed in order to diagnose telangiectases in the gastric and duodenal mucosa (15) ; capillary microscopy can be used to detect telangectases of the nail fold (4) .
Dentistry in HHTpatients
Since the most common immunological route for the entry of bacteria into the blood stream is from the gingival mucosa, it is very important to inform the dentist before any dental work, including dental cleaning. If pulmonary AVMs are present, the bacteria, once in the bloodstream, can pass through them and may lodge in the brain and cause a brain abscess. A brain abscess is an extremely serious medical emergency and could be life threatening. If an HHT patient has not been specifically screened for lung AVMs, to prevent a brain abscess antibiotics must be taken prior to any dental procedure (1 hour before dental work). It is essential that patients with HHT receive antibiotics before dental cleaning or dental work of any kind.
It is important that the HHT patient also discusses with the dentist and dental hygienist any homecare procedures or devices that have been recommended, such as oral irrigation, or any procedures that could introduce bacteria into the bloodstream (American Heart Association Guidelines).
Furthermore, there are medications that should not be routinely prescribed for HHT patients. Dental workers should be aware ofthese. Anti-inflammatory agents should generally not be taken by individuals with HHT because these medications can increase bleeding. Often these medications are prescribed following dental procedures. Telangiectases of the gingival mucosa, hard and soft palate, lips and tongue, are often mistakenly called red spots upon oral examination. They can vary in size ( Fig. 3, 4 ). Procedures involving minor tissue manipulation such as having teeth cleaned, brushing teeth and using dental floss at home can cause bleeding. The dental worker should pay attention to the bleeding and rule out gingivitis, periodontal diseases or bacterial infection. Telangiectases related to HHT in the mouth and lips can be acquired in adulthood. The dental health worker is therefore in a position to identify telangiectases (7) .
Pathogenesis ofHHT
In normal skin, arterioles in the papillary dermis are connected to venules through multiple capillaries. These vessels arise from larger arterioles and venules at the junction of the dermis and fat. In the earliest stage of cutaneous telangiectasia, a single venule becomes dilated but it is still connected to an arteriola through one or more capillaries.
Two genes are responsible for HHT, ENG (Endoglin) (Online Mendelian Inheritance in Man), (OMIM*131195) mutated in HHT 1 (16) (OMIM*187300) map along the long arm of the chromosome 9 (9 q33-q34.1) and ACVRLI (activin receptor-like kinase 1, also known as ALK-l) (OMIM*601284), mutated in HHT 2 (17) . (OMIM*600376), located on the long arm of the chromosome 12 (12 ql l-q l-l) HHT 1 is associated with a higher incidence of pulmonary AVMs than HHT 2, which generally has a later onset (3). Both gene s are expressed predominantly in endothelial cells. To date , more than 100 different mutations have been identified in the ENG gene (I8-20), and the number of different mutations reported in the ALK -I gene is also more than 100 (20) (21) . Almost all the mutations reported are unique for a parti cular famil y. So far, numerous mutations of ENG and ALK-l gene have been described and, with few exceptions, mutations tend to be unique and family specific (18) . The severity of HHT is not correlated with the type of mutation or its posit ion (22) . Mutated ENG is rarely expressed in HHT I patients and , if expressed, it is only as an intracellular species (23) . The current model for HHT 1 is haploinsuffici ency, because of reduced levels of functional endoglin at the surface of endothelial cells (19, (23) (24) (25) (26) . Haploinsufficiency in ALK-I also seems to be associated with HHT 2 (27) .
Murine model s have been obtained by engineering mice lacking one or both copie s of endoglin (End) or ALKI gene . A crucial role for endoglin and activin-receptor like kinase I in angiogenesis was demonstrated in mice deficient in both copies of Endoglir, or ALK I gene respectively, which showed multiple vascular and cardiac defects leading to death in early embryos (28) (29) (30) (31) . The murine model of HHT reproduces the human disea se and can help to elucidate the mechanisms that lead to the initiation and progression of vascular abnormalities. For example, cutaneous telangiectases are found in 90% of heterozygous (End+/-) mice with HHT. A telangiectasia arise s from the dilation of a postcapillary venule and direct fusion with an arteriole, bypassing the capillary network (32) . This implies that regulation of the normal angiogenic process of vessel branching is altered in HHT. The 50% reduction in endoglin or Alk-l present in endothelial cells of all vessels of individuals with mutation of one of these genes (9, (11) (12) , and in mice engineered to express a single allele of these genes, therefore predisposes vessels to dilation. However, additional genetic and environmental factors seem necessary to trigger the development of vascular abnormalities as suggested by their heterogeneity in humans and mice with a single functional copy of endoglin or ALK-I gene.
Both endoglin and ALK-I are components of the transforming growth factor (TGF-~) superfamily of receptors that are predominantly expressed on vascular endothelium. TGF-~1 superfamily members bind to heteromeric complexes of type I and II transmembrane serine/threonine kinase receptors (33) . Upon ligand binding, type II receptors recruit and transphosphorylate type I receptors, which subsequently activate downstream signal mediators, Smads. Only one TGF-~type II receptor (TR-II) is present in mammals, whereas two type I receptors appear to serve as TGF-~type I receptors. Activin receptor-like kinase 5 (ALK-5) is a TGF-~type I receptor ubiquitously expressed in TGF-~responsive cells. ALK-5 mediates TGF-~signaling through phosphorylating Smad2/Smad3. In addition, another type I receptor, ALK-I, is expressed in endothelial cells and binds to TGF-~and possibly other ligands (34) . ALK-I signals are transduced through Smadll SmadS, which are major downstream mediators of BMPs. Thus, in endothelial cells, ALK-5 and ALK-I mediate TGF-~signaling through distinct transcriptional regulation of target genes. TGF-~1 plays a very important role in the development of the vascular system, affecting functions of endothelial cells (35) . The cellular responses mediated by TGF-1are complex and can be stimulatory or inhibitory, depending on cell type and conditions. TGF-~1 generally inhibits proliferation and migration of endothelial cells, but potently stimulates extracellular matrix (ECM) production. Importantly, TGF-~1 is essential for the recruitment and regulation of pericytes and smooth muscle cells, which lead to vascular maturation and stabilization (36) . TGF-~1 acts by autocrine and paracrine mechanisms that are likely relevant in the pathogenesis of HHT.
TGF-~1 stimulates the activity of its own promoter, and this autoregulation might explain the prolongation of secretion and autocrine action ofTGF-~1 after an initial stimulus (37) . It has been demonstrated (38) that endothelial cells from End+/mice secrete less TGF-~1 than normal cells, and it has been proposed that the level of endoglin could control this autoregulatory pathway. Less endoglin would then lead to reduced autocrine effects ofTGF-1. A decrease in both local and circulating TGF-1 levels will lead to unstable cellular interactions in the vessel wall, dilated vessels and vascular abnormalities. Such alterations could impair other angiogenic regulatory mechanisms and lead to deterioration ofthe vascular network associated with the progression of HHT. Reduced TGF-~1 levels hence play a role in the vascular remodelling of cerebral and pulmonary human AVMs which leads to extremely dilated and tortuous vessels with variable, and sometimes excessive, layers of smooth-muscle cells without elastic fibers, disorganized adventitia and active angiogenesis (12) . A dysregulation in the mechanisms responsible for maintaining interactions between intimal, medial, and adventitial layers of vessels can therefore likely cause the progression and expansion of vascular lesions.
Endoglin and ALK-1 genes are both essential for normal angiogenesis and vasculogenesis but the molecular mechanisms regulating the expression of them are not well understood. Recently (39) it was observed that ENG gene is actively transcribed in vascular smooth muscle cells whose proliferation is dramatically altered in HHT patients, the ENG protein also being present, although at low levels.
To date, there are no data on ENG and ALK-1 gene expression patterns in normal subjects nor in HHT patients. Similarly, little is known about intracellular proteins able to interact with ALK-1 and ENG gene products. A recent paper (40) reports an ALK-1 dependent upregulation of ENG (40) Id1 and Id2 (41) genes in the endothelial cells. Finally, even if the presence of modifier genes has been hypothesized, so far no candidates have been identified, therefore the genetic factors correlating with the wide variation, both intra-and inter-familial, in clinical symptoms remain unknown. However, within families there is considerable inter-and intra-familial variability with respect to age-related penetrance and pattern of clinical expression of the disease. Recently, mutations in the MADH4 gene in patients that show clinical features of both HHT and juvenile polyposis was reported (42) .
MADH4 codes for the protein SMAD4 and is expressed in a variety of cell types. The protein has a role in the TGF-p pathway, like ENG andALK-l, as well as in the bone-morpho genic-protein pathway. HHT, as part of this syndrome, can thus be explained by MADH4 mutations.
Alternatively, more extensive locus heterogeneity may playa role. A few families have been described that show no significant linkage to either ENG or ALK-I (43) (44) (45) . After re-evaluating all the members in the family studied by Piantanida and Buscarini, the evidence for exclusion of chromosome 12 was no longer considered significant and analysis revealed an ALK-l mutation (p.R67W) (46) . However, the presence of a third locus cannot be ruled out. In this respect, the finding of a new locus (HHT-3) maps to chromosome 5 in screened HHT families with no mutations in ENG or ALK-l, but with clinical manifestations, renders it a new candidate gene (47) .
CONCLUSIONS
HHT is an autosomal-dominantly-inherited vascular dysplasia characterized by age-dependant incomplete penetrance and variable expressivity, with clinical manifestations consisting in epistaxis, gastrointestinal bleeding and AVMs. Morbidity of HHT is often due to complications of AVMs, such as stroke or haemorrhage, also known to occur in children. Many authors have reported successful treatments of AVMs, which resulted in a significant decrease of life-threatening complications and HHT morbidity. Since early diagnosis permits an appropriate care of affected subjects, a very sensitive mutation screening technique is required to identify the mutation carriers among all at-risk individuals belonging to HHT-families. For this purpose, many different techniques have been utilized for mutation screening of endoglin and ALKI genes, responsible for HHT-l and HHT-2, respectively.
The identification of the disease-causing mutations in a large panel of HHT families provides us with a good basis for studying in detail the phenotype-genotype relationship for both ENG and ALK-l within and between families. In this way it is possible to gain more insight into the variability of clinical expression and the factors contributing to HHT. The nature of the practice of odonstomatology necessitates a broad understanding of the systemic diseases reflected in the immune system during normal dental practice. Hereditary hemorrhagic telangiectasia is one such disease.
